Thursday, July 16, 2026

11:15 AM - 1:15 PM

---

Details

The most common form of heart failure in women is heart failure with preserved ejection fraction (HFpEF). Despite this, females are under-represented in clinical and preclinical studies, and current HFpEF management is not sex-specific. Affected patients exhibit shortness of breath, elevated cardiac BNP and poor survival rates, despite no impairment in ejection fraction (EF). No current approved interventions reduce mortality or improve recovery from HFpEF. This symposium is designed to consider whether pharmacotherapy for the most common forms of heart failure, and indeed heart failure in general, should be considered on the basis of biological sex, and which existing or potential new pharmacotherapies offer promise for improving prognosis in affected women.

---

Session chair